Latest
1752vc1752vc|Deviation Capital Launches with $2B AUM to Back AI, Robotics, and Deep Tech StartupsDeviation Capital Launches with $2B AUM to Back AI, Robotics, and Deep Tech Startups|ParcelBio Raises $13M Seed to Advance Durable mRNA Platform for Autoimmune and Oncology TherapiesParcelBio Raises $13M Seed to Advance Durable mRNA Platform for Autoimmune and Oncology Therapies|DISHIO Raises $2.5M Seed to Power AI-Driven Restaurant Marketing and Customer RetentionDISHIO Raises $2.5M Seed to Power AI-Driven Restaurant Marketing and Customer Retention|a16z Crypto Launches $2.2B Fund to Invest in Blockchain and Financial Infrastructurea16z Crypto Launches $2.2B Fund to Invest in Blockchain and Financial Infrastructure|Restive Ventures Raises $45M Fund III to Back AI-Native Financial Services StartupsRestive Ventures Raises $45M Fund III to Back AI-Native Financial Services Startups|5th Century Partners Closes $276M Fund II to Invest in Lower Middle Market Healthcare and Services5th Century Partners Closes $276M Fund II to Invest in Lower Middle Market Healthcare and Services|Pit Raises $16M Seed to Build AI-Driven Internal Systems for Enterprise OperationsPit Raises $16M Seed to Build AI-Driven Internal Systems for Enterprise Operations|Lunar Outpost Raises $30M Series B to Scale Lunar Mobility and Space Infrastructure SystemsLunar Outpost Raises $30M Series B to Scale Lunar Mobility and Space Infrastructure Systems|Anagram Secures $250M to Develop Next-Generation Enzyme Therapy for Cystic FibrosisAnagram Secures $250M to Develop Next-Generation Enzyme Therapy for Cystic Fibrosis|1752vc1752vc|Deviation Capital Launches with $2B AUM to Back AI, Robotics, and Deep Tech StartupsDeviation Capital Launches with $2B AUM to Back AI, Robotics, and Deep Tech Startups|ParcelBio Raises $13M Seed to Advance Durable mRNA Platform for Autoimmune and Oncology TherapiesParcelBio Raises $13M Seed to Advance Durable mRNA Platform for Autoimmune and Oncology Therapies|DISHIO Raises $2.5M Seed to Power AI-Driven Restaurant Marketing and Customer RetentionDISHIO Raises $2.5M Seed to Power AI-Driven Restaurant Marketing and Customer Retention|a16z Crypto Launches $2.2B Fund to Invest in Blockchain and Financial Infrastructurea16z Crypto Launches $2.2B Fund to Invest in Blockchain and Financial Infrastructure|Restive Ventures Raises $45M Fund III to Back AI-Native Financial Services StartupsRestive Ventures Raises $45M Fund III to Back AI-Native Financial Services Startups|5th Century Partners Closes $276M Fund II to Invest in Lower Middle Market Healthcare and Services5th Century Partners Closes $276M Fund II to Invest in Lower Middle Market Healthcare and Services|Pit Raises $16M Seed to Build AI-Driven Internal Systems for Enterprise OperationsPit Raises $16M Seed to Build AI-Driven Internal Systems for Enterprise Operations|Lunar Outpost Raises $30M Series B to Scale Lunar Mobility and Space Infrastructure SystemsLunar Outpost Raises $30M Series B to Scale Lunar Mobility and Space Infrastructure Systems|Anagram Secures $250M to Develop Next-Generation Enzyme Therapy for Cystic FibrosisAnagram Secures $250M to Develop Next-Generation Enzyme Therapy for Cystic Fibrosis
Back to articles

Attaboy Labs Secures Strategic Backing in Friends & Family Round to Scale Daily Performance Supplement

Attaboy does not ask for attention, it earns it one scoop at a time. Attaboy Labs, Inc., out of Westwood, Massachusetts, just pulled in a Friends and Family round led by Malar Group, with Sayan Navaratnam backing the play. No vanity metrics, no funding theatrics, just a clean signal in a noisy aisle. Credit to Founder and CEO Nick Lawhon for building something that reads less like a supplement brand and more like a point of view you can mix with water.

Every Damn Day is exactly what it sounds like. 1 scoop, 14 research backed ingredients, no proprietary smoke screens, no caffeine crutch. It is hydration, focus, recovery, and performance without turning your kitchen counter into a chemistry set. In a market that profits off confusion, clarity is a competitive advantage, and most players are still selling fog with a side of neon packaging.

The interesting part is not just the product, it is how it got here. Nick Lawhon did not come up through the usual wellness echo chamber, bringing creative DNA, storytelling instincts, and a bias toward cutting the fluff. That shows up in the formulation and the brand, and when you build for the guy who is tired of being sold to, you better have receipts. Attaboy does, and that is why a firm like Malar Group leans in early instead of waiting for consensus to make it safe.

Friends and Family rounds are usually quiet affairs, but this one carries a little more weight. When an institutional name steps into that circle, it is less about the check size and more about conviction. Malar Group is not just wiring capital, they are stepping in as a strategic partner to help push product, expand the roadmap, and open the door to Canada next. Geography follows belief, and belief here is grounded in something simple, make it work, make it honest, make it repeatable, then scale it without losing the plot.

There is a lesson tucked in here for anyone building in consumer. You do not need 10 SKUs and a celebrity contract to get attention, you need 1 product that earns its name every damn day. You need positioning that a real person recognizes in 5 seconds, and the discipline to say no to everything that dilutes that signal, even when the market tempts you with shortcuts dressed up as strategy.

Attaboy is betting that less noise equals more trust, and Malar Group is betting that trust compounds. The rest of the market is still arguing over flavors and fonts while this team is tightening the formula and widening the lane, and that tension usually ends one way.